drugset / Trial / NCT06231277
Phase I Clinical Trial of BH002 in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to about in Patients With Advanced Solid Tumors. The main question\[s\] it aims to answer are: * question 1:Evaluating the tolerability of BH002 injection in Chinese patients with advanced solid tumors * question 2:Obtain the pharmacokinetic (PK) characteristics of BH002 injection in Chinese patients with advanced solid tumors
Timeline
- Start
- 2022-04-26
- Primary completion
- 2023-03-10
- Completion
- 2023-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BH002 | Unknown | 15 mg/m2 | Intravenous |
| Subject | BH002 | Unknown | 20 mg/m2 | Intravenous |
| Subject | BH002 | Unknown | 25 mg/m2 | Intravenous |
| Subject | BH002 | Unknown | 30 mg/m2 | Intravenous |
| Subject | BH002 | Unknown | 35 mg/m2 | Intravenous |